Advanced in Essential Thrombocythemia

Dr. Sameer Z. Ahmed

Franciscan Physician Network
Lafayette, IN
Advanced
in Essential Thrombocythemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Sameer Ahmed is a Hematologist Oncology specialist and a Hematologist in Lafayette, Indiana. Dr. Ahmed and is rated as an Advanced provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Childhood Iron Deficiency Anemia, Bone Marrow Aspiration, and Nephrectomy. Dr. Ahmed is currently accepting new patients.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Putnam County Hospital
Franciscan Health Rensselaer, Inc
Franciscan Health Mooresville
Franciscan Health Indianapolis
Languages Spoken
English
Armenian
Mandarin
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  CareSource
  •  Humana

Locations

FRANCISCAN PHYSICIAN NETWORK
1701 S Creasy Ln, 1w93, Lafayette, IN 47905
765-502-4015

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drug: Sotorasib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages
A Prospective, Multicenter Atherectomy Study Showing Luminal Gain in Subjects With Peripheral Vascular Blockages
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Device
Study Phase: Not Applicable
View 5 Less Clinical Trials
Similar Doctors
Expertise in
93
conditions
Dr. Mary L. Mayer
Oncology | Hematology | Hematology Oncology
Expertise in
93
conditions
Dr. Mary L. Mayer
Oncology | Hematology | Hematology Oncology

Community Physicians Of Indiana Inc

7229 Clearvista Dr, Symptom Management Group, 
Indianapolis, IN 
 (54.1 mi)
317-621-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mary Mayer is an Oncologist and a Hematologist in Indianapolis, Indiana. Dr. Mayer and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Shwartzman Phenomenon, Bone Marrow Aspiration, and Endoscopy. Dr. Mayer is currently accepting new patients.

Expertise in
52
conditions
Dr. Edmond A. Bendaly
Hematology Oncology | Hematology | Oncology
Expertise in
52
conditions
Dr. Edmond A. Bendaly
Hematology Oncology | Hematology | Oncology

Marion General Hospital

831 N Theatre Dr, 
Marion, IN 
 (61.8 mi)
765-660-7800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Edmond Bendaly is a Hematologist Oncology specialist and a Hematologist in Marion, Indiana. Dr. Bendaly and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Midline Lethal Granuloma, and Thrombocytopenia. Dr. Bendaly is currently accepting new patients.

Expertise in
56
conditions
Dr. Daniel T. Milton
Hematology Oncology | Oncology | Hematology
Expertise in
56
conditions
Dr. Daniel T. Milton
Hematology Oncology | Oncology | Hematology

American Oncology Partners PA

8301 Harcourt Rd, Suite 200, 
Indianapolis, IN 
 (47.7 mi)
317-415-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Milton is a Hematologist Oncology specialist and an Oncologist in Indianapolis, Indiana. Dr. Milton and is rated as a Distinguished provider by MediFind in the treatment of Essential Thrombocythemia. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Childhood Iron Deficiency Anemia, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Milton is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile